Healthy Adult Participants
Conditions
Brief summary
The purpose of this study is to evaluate the bioequivalence of a single oral administration of a vortioxetine (Lu AA21004) 20 mg tablet in comparison with two of vortioxetine 10 mg tablets in Japanese healthy adult participants.
Detailed description
The drug being tested in this study is called vortioxetine (Lu AA21004). Vortioxetine is being tested in Japanese healthy adult participants. This study will look at the bioequivalence of a single oral administration of a vortioxetine 20 mg tablet in comparison with two of vortioxetine 10 mg tablets, and also look at the safety of a single oral dose of vortioxetine 20 mg in Japanese healthy adult participants. The study will enroll 28 (14 for each sequence) healthy participants. In case bioequivalence cannot be demonstrated with the number of participants initially planned, an add-on participant study may be conducted (as a maximum 28 participants additionally). Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups. * Treatment Group A: Vortioxetine 20 mg (one 20 mg tablet) in Period 1 + Vortioxetine 20 mg (two 10 mg tablets) in Period 2 * Treatment Group B: Vortioxetine 20 mg (two 10 mg tablets) in Period 1 + Vortioxetine 20 mg (one 20 mg tablet) in Period 2 This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 25 days. Participants will make two visits to the clinic and be hospitalized for ten days in total.
Interventions
DRUGVortioxetine
Vortioxetine tablet
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Be a healthy Japanese adult volunteer. 2. Understand the contents of the study and is capable of providing written consent to participate in the study. 3. Be willing to comply with all study procedures and restrictions. 4. Aged between ≥20 and ≤45 years at the time of screening. 5. Have a BMI of ≥18.5 and ≤24.9 (kg/m\^2) and a body weight of ≥50 kg at the time of screening. 6. Be a extensive metabolizer (EM) based on CYP2D6 genotyping at the time of screening. 7. A female participant of childbearing potential with a non-sterilized male partner must agree to routinely use appropriate contraception during the study from the time of signing informed consent until 4 weeks after last dosing of the study drug.
Exclusion criteria
1. Has received any investigational drug within 90 days before screening for this study. 2. Previously received Lu AA21004 before participation in this study. 3. Is an employee of the sponsor or the study site, or immediate family member, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or who may be coerced to provide consent. 4. Has uncontrolled, clinically relevant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which may affect study participation or study results. 5. Has a history of multiple episodes or severe allergies (eg, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription drugs, over the counter (OTC) drugs, or foods. 6. Has a positive pregnancy test at the time of screening or Day -1. 7. Is a pregnant or lactating female. 8. Has a positive urine drug screen test at the time of screening or Day -1. 9. Has a history of drug abuse (defined as any illicit drug use) or has a history of alcohol dependence within 2 years before the start of screening or is unwilling to agree to abstain from alcohol and drugs throughout the study. 10. Consumes 6 or more servings of caffeinated beverages (containing about 120 mg of caffeine per serving) such as of coffee, tea, cola, or energy drinks. 11. Is a smoker who smoked cigarettes or used nicotine-containing products (such as nicotine patch) within 6 months before the Period 1 study drug administration. 12. Used any of the excluded drugs, dietary products or foods during the specified time periods, or will need any of them during the study period. 13. Has any current or recent gastrointestinal diseases that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent \[more than once per week\] occurrence of heartburn), or any surgical intervention (Stomach, cholecystectomy etc.). 14. Has a history of cancer. 15. Has a positive test result for any of the following at the time of screening: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, serological test for syphilis. 16. Has poor peripheral venous access. 17. Has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to the start of Period 1 study drug administration. 18. Has undergone whole blood collection of at least 800 mL in total within 52 weeks (364 days) prior to the start of Period 1 study drug administration. 19. Has undergone blood component collection within 2 weeks (14 days) prior to the start of Period 1 study drug administration. 20. Has any clinically relevant abnormality in vital signs or 12-lead electrocardiograms (ECG) at screening or on Day -1 of Period 1. 21. Has abnormal laboratory test values at screening or on Day -1 of Period 1 indicating clinically relevant underlying disease, or showing alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>1.5×upper limit of normal (ULN). 22. Is unlikely to comply with the protocol requirements or is unsuitable as a participant of this study for any other reason in the opinion of the investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
Secondary
| Measure | Time frame |
|---|---|
| MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
| Number of Participants With TEAE Related to Vital Sign | Up to Day 25 |
| Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased) | Up to Day 25 |
| Number of Participants With TEAE Related to 12-lead Electrocardiograms | Up to Day 25 |
| Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | Up to Day 25 |
| Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004 | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose |
Countries
Japan
Participant flow
Recruitment details
Participants took part in the study at 1 investigative site in Japan, from 16 February 2018 to 13 April 2018.
Pre-assignment details
Healthy participants were enrolled in one of two treatment group (vortioxetine 20 mg (1×20 mg tablet) on Day 1 in Period 1, followed by vortioxetine 20 mg (2×10 mg tablets) on Day 1 in Period 2; vortioxetine 20 mg (2×10 mg tablets) on Day 1 in Period 1, followed by vortioxetine 20 mg (1×20 mg tablet) on Day 1 in Period 2) with cross over design.
Participants by arm
| Arm | Count |
|---|---|
| Vortioxetine One 20 mg Tablet + Two 10 mg Tablets Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 2 in a fasted state. | 14 |
| Vortioxetine Two 10 mg Tablets + One 20 mg Table Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 2 in a fasted state. | 14 |
| Total | 28 |
Baseline characteristics
| Characteristic | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Age, Continuous | 24.0 Years STANDARD_DEVIATION 6.52 | 24.0 Years STANDARD_DEVIATION 4.96 | 24.0 Years STANDARD_DEVIATION 5.68 |
| Alcohol Classification Drank 2 to 3 Days a Month | 9 Participants | 8 Participants | 17 Participants |
| Alcohol Classification Drank 2 to 3 Days a Week | 3 Participants | 0 Participants | 3 Participants |
| Alcohol Classification Never Drank | 2 Participants | 6 Participants | 8 Participants |
| BMI | 21.46 kg/meter (m)^2 STANDARD_DEVIATION 1.812 | 21.33 kg/meter (m)^2 STANDARD_DEVIATION 1.175 | 21.39 kg/meter (m)^2 STANDARD_DEVIATION 1.5 |
| Caffeine Classification Had Caffeine Consumption | 5 Participants | 4 Participants | 9 Participants |
| Caffeine Classification Had no Caffeine Consumption | 9 Participants | 10 Participants | 19 Participants |
| Height | 172.4 Centimeters (cm) STANDARD_DEVIATION 3.94 | 170.2 Centimeters (cm) STANDARD_DEVIATION 6.48 | 171.3 Centimeters (cm) STANDARD_DEVIATION 5.38 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment Japan | 14 Participants | 14 Participants | 28 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 14 Participants | 14 Participants | 28 Participants |
| Smoking Classification Ex-Smoker | 2 Participants | 1 Participants | 3 Participants |
| Smoking Classification Never Smoked | 12 Participants | 13 Participants | 25 Participants |
| Weight | 63.86 Kilograms (kg) STANDARD_DEVIATION 6.694 | 61.91 Kilograms (kg) STANDARD_DEVIATION 6.254 | 62.89 Kilograms (kg) STANDARD_DEVIATION 6.434 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 0 / 28 |
| other Total, other adverse events | 1 / 28 | 0 / 28 |
| serious Total, serious adverse events | 0 / 28 | 0 / 28 |
Outcome results
Primary
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004 | 299.3 hour*nanogram per milliliter (h*ng/mL) | Standard Deviation 59.82 |
| Vortioxetine Two 10 mg Tablets | AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004 | 301.1 hour*nanogram per milliliter (h*ng/mL) | Standard Deviation 62.07 |
90% CI: [0.967, 1.026]ANOVA
Primary
Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004 | 8.744 ng/mL | Standard Deviation 1.7838 |
| Vortioxetine Two 10 mg Tablets | Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004 | 8.976 ng/mL | Standard Deviation 1.6936 |
90% CI: [0.937, 1.008]ANOVA
Secondary
AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004 | 463.9 h*ng/mL | Standard Deviation 135.58 |
| Vortioxetine Two 10 mg Tablets | AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004 | 477.6 h*ng/mL | Standard Deviation 164.83 |
Secondary
MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004 | 67.27 Hours | Standard Deviation 14.145 |
| Vortioxetine Two 10 mg Tablets | MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004 | 68.84 Hours | Standard Deviation 18.646 |
Secondary
MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004 | 30.12 Hours | Standard Deviation 1.8274 |
| Vortioxetine Two 10 mg Tablets | MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004 | 30.12 Hours | Standard Deviation 1.8335 |
Secondary
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
Time frame: Up to Day 25
Population: Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vortioxetine One 20 mg Tablet | Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | 1 Participants |
| Vortioxetine Two 10 mg Tablets | Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | 0 Participants |
Secondary
Number of Participants With TEAE Related to 12-lead Electrocardiograms
Time frame: Up to Day 25
Population: Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vortioxetine One 20 mg Tablet | Number of Participants With TEAE Related to 12-lead Electrocardiograms | 0 Participants |
| Vortioxetine Two 10 mg Tablets | Number of Participants With TEAE Related to 12-lead Electrocardiograms | 0 Participants |
Secondary
Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)
Time frame: Up to Day 25
Population: Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vortioxetine One 20 mg Tablet | Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased) | 1 Participants |
| Vortioxetine Two 10 mg Tablets | Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased) | 0 Participants |
Secondary
Number of Participants With TEAE Related to Vital Sign
Time frame: Up to Day 25
Population: Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vortioxetine One 20 mg Tablet | Number of Participants With TEAE Related to Vital Sign | 0 Participants |
| Vortioxetine Two 10 mg Tablets | Number of Participants With TEAE Related to Vital Sign | 0 Participants |
Secondary
T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004 | 45.36 Hours | Standard Deviation 9.7694 |
| Vortioxetine Two 10 mg Tablets | T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004 | 46.44 Hours | Standard Deviation 13.09 |
Secondary
Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Vortioxetine One 20 mg Tablet | Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004 | 6.000 Hours |
| Vortioxetine Two 10 mg Tablets | Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004 | 6.000 Hours |
Secondary
λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Population: Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004 | 0.01608 1/Hours | Standard Deviation 0.004009 |
| Vortioxetine Two 10 mg Tablets | λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004 | 0.01599 1/Hours | Standard Deviation 0.0041766 |